Does the media favor AGIO or RYTM?

In the previous week, Rhythm Pharmaceuticals had 1 more articles in the media than Agios Pharmaceuticals. MarketBeat recorded 9 mentions for Rhythm Pharmaceuticals and 8 mentions for Agios Pharmaceuticals. Agios Pharmaceuticals' average media sentiment score of 1.43 beat Rhythm Pharmaceuticals' score of 1.38 indicating that Agios Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Agios Pharmaceuticals 7 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rhythm Pharmaceuticals 8 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ORKA or AGIO?

In the previous week, Oruka Therapeutics had 5 more articles in the media than Agios Pharmaceuticals. MarketBeat recorded 13 mentions for Oruka Therapeutics and 8 mentions for Agios Pharmaceuticals. Agios Pharmaceuticals' average media sentiment score of 1.43 beat Oruka Therapeutics' score of 1.18 indicating that Agios Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oruka Therapeutics 9 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Agios Pharmaceuticals 7 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer AGIO or CGON?

In the previous week, CG Oncology had 2 more articles in the media than Agios Pharmaceuticals. MarketBeat recorded 10 mentions for CG Oncology and 8 mentions for Agios Pharmaceuticals. CG Oncology's average media sentiment score of 1.43 beat Agios Pharmaceuticals' score of 1.43 indicating that CG Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Agios Pharmaceuticals 7 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CG Oncology 9 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor AGIO or SRRK?

In the previous week, Agios Pharmaceuticals had 1 more articles in the media than Scholar Rock. MarketBeat recorded 8 mentions for Agios Pharmaceuticals and 7 mentions for Scholar Rock. Scholar Rock's average media sentiment score of 1.43 beat Agios Pharmaceuticals' score of 1.43 indicating that Scholar Rock is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Agios Pharmaceuticals 7 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Scholar Rock 6 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to AGIO or COGT?

In the previous week, Agios Pharmaceuticals had 3 more articles in the media than Cogent Biosciences. MarketBeat recorded 8 mentions for Agios Pharmaceuticals and 5 mentions for Cogent Biosciences. Cogent Biosciences' average media sentiment score of 1.57 beat Agios Pharmaceuticals' score of 1.43 indicating that Cogent Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Agios Pharmaceuticals 7 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cogent Biosciences 4 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Agios Pharmaceuticals (AGIO) Competitors

$33.13 -1.00 (-2.93%)

As of 04:00 PM Eastern

Compare

AGIO vs. RYTM, ORKA, CGON, SRRK, and COGT

Should you buy Agios Pharmaceuticals stock or one of its competitors? Agios Pharmaceuticals's main competitors and comparable companies include Rhythm Pharmaceuticals (RYTM), Oruka Therapeutics (ORKA), CG Oncology (CGON), Scholar Rock (SRRK), and Cogent Biosciences (COGT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Agios Pharmaceuticals compare to Rhythm Pharmaceuticals?

Agios Pharmaceuticals (NASDAQ:AGIO) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, earnings, valuation, media sentiment, analyst recommendations, institutional ownership and profitability.

Rhythm Pharmaceuticals has higher revenue and earnings than Agios Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Agios Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agios Pharmaceuticals	$98.34M	20.11	-$412.78M	-$7.01	N/A
Rhythm Pharmaceuticals	$189.76M	37.88	-$196.54M	-$3.11	N/A

In the previous week, Rhythm Pharmaceuticals had 1 more articles in the media than Agios Pharmaceuticals. MarketBeat recorded 9 mentions for Rhythm Pharmaceuticals and 8 mentions for Agios Pharmaceuticals. Agios Pharmaceuticals' average media sentiment score of 1.43 beat Rhythm Pharmaceuticals' score of 1.38 indicating that Agios Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Agios Pharmaceuticals	7 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rhythm Pharmaceuticals	8 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Agios Pharmaceuticals has a beta of 0.6, indicating that its share price is 40% less volatile than the broader market. Comparatively, Rhythm Pharmaceuticals has a beta of 1.97, indicating that its share price is 97% more volatile than the broader market.

Rhythm Pharmaceuticals has a net margin of -85.59% compared to Agios Pharmaceuticals' net margin of -418.24%. Agios Pharmaceuticals' return on equity of -35.67% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Agios Pharmaceuticals	-418.24%	-35.67%	-33.06%
Rhythm Pharmaceuticals	-85.59%	-159.87%	-44.00%

Agios Pharmaceuticals currently has a consensus target price of $41.25, suggesting a potential upside of 24.51%. Rhythm Pharmaceuticals has a consensus target price of $141.12, suggesting a potential upside of 34.54%. Given Rhythm Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Rhythm Pharmaceuticals is more favorable than Agios Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agios Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.55
Rhythm Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.74

Summary

Rhythm Pharmaceuticals beats Agios Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

How does Agios Pharmaceuticals compare to Oruka Therapeutics?

Oruka Therapeutics (NASDAQ:ORKA) and Agios Pharmaceuticals (NASDAQ:AGIO) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, earnings, media sentiment, analyst recommendations, institutional ownership and profitability.

In the previous week, Oruka Therapeutics had 5 more articles in the media than Agios Pharmaceuticals. MarketBeat recorded 13 mentions for Oruka Therapeutics and 8 mentions for Agios Pharmaceuticals. Agios Pharmaceuticals' average media sentiment score of 1.43 beat Oruka Therapeutics' score of 1.18 indicating that Agios Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oruka Therapeutics	9 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Agios Pharmaceuticals	7 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Oruka Therapeutics currently has a consensus target price of $133.00, suggesting a potential upside of 46.17%. Agios Pharmaceuticals has a consensus target price of $41.25, suggesting a potential upside of 24.51%. Given Oruka Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Oruka Therapeutics is more favorable than Agios Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oruka Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82
Agios Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.55

56.4% of Oruka Therapeutics shares are held by institutional investors. 23.5% of Oruka Therapeutics shares are held by insiders. Comparatively, 5.4% of Agios Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Oruka Therapeutics has higher earnings, but lower revenue than Agios Pharmaceuticals. Oruka Therapeutics is trading at a lower price-to-earnings ratio than Agios Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oruka Therapeutics	N/A	N/A	-$105.43M	-$2.03	N/A
Agios Pharmaceuticals	$98.34M	20.11	-$412.78M	-$7.01	N/A

Oruka Therapeutics has a beta of -0.34, suggesting that its stock price is 134% less volatile than the broader market. Comparatively, Agios Pharmaceuticals has a beta of 0.6, suggesting that its stock price is 40% less volatile than the broader market.

Oruka Therapeutics has a net margin of 0.00% compared to Agios Pharmaceuticals' net margin of -418.24%. Oruka Therapeutics' return on equity of -21.65% beat Agios Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oruka Therapeutics	N/A	-21.65%	-20.88%
Agios Pharmaceuticals	-418.24%	-35.67%	-33.06%

Summary

Oruka Therapeutics beats Agios Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does Agios Pharmaceuticals compare to CG Oncology?

Agios Pharmaceuticals (NASDAQ:AGIO) and CG Oncology (NASDAQ:CGON) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, analyst recommendations, valuation, media sentiment, institutional ownership and profitability.

26.6% of CG Oncology shares are held by institutional investors. 5.4% of Agios Pharmaceuticals shares are held by insiders. Comparatively, 4.8% of CG Oncology shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Agios Pharmaceuticals presently has a consensus price target of $41.25, suggesting a potential upside of 24.51%. CG Oncology has a consensus price target of $83.18, suggesting a potential upside of 11.91%. Given Agios Pharmaceuticals' higher probable upside, equities research analysts clearly believe Agios Pharmaceuticals is more favorable than CG Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agios Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.55
CG Oncology	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77

CG Oncology has lower revenue, but higher earnings than Agios Pharmaceuticals. CG Oncology is trading at a lower price-to-earnings ratio than Agios Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agios Pharmaceuticals	$98.34M	20.11	-$412.78M	-$7.01	N/A
CG Oncology	$4.04M	1,630.84	-$160.99M	-$2.69	N/A

Agios Pharmaceuticals has a net margin of -418.24% compared to CG Oncology's net margin of -3,602.68%. CG Oncology's return on equity of -25.20% beat Agios Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Agios Pharmaceuticals	-418.24%	-35.67%	-33.06%
CG Oncology	-3,602.68%	-25.20%	-23.98%

In the previous week, CG Oncology had 2 more articles in the media than Agios Pharmaceuticals. MarketBeat recorded 10 mentions for CG Oncology and 8 mentions for Agios Pharmaceuticals. CG Oncology's average media sentiment score of 1.43 beat Agios Pharmaceuticals' score of 1.43 indicating that CG Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Agios Pharmaceuticals	7 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CG Oncology	9 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Agios Pharmaceuticals has a beta of 0.6, indicating that its share price is 40% less volatile than the broader market. Comparatively, CG Oncology has a beta of 0.24, indicating that its share price is 76% less volatile than the broader market.

Summary

CG Oncology beats Agios Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

How does Agios Pharmaceuticals compare to Scholar Rock?

Agios Pharmaceuticals (NASDAQ:AGIO) and Scholar Rock (NASDAQ:SRRK) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, institutional ownership, valuation, dividends, earnings, profitability and media sentiment.

Scholar Rock has lower revenue, but higher earnings than Agios Pharmaceuticals. Scholar Rock is trading at a lower price-to-earnings ratio than Agios Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agios Pharmaceuticals	$98.34M	20.11	-$412.78M	-$7.01	N/A
Scholar Rock	N/A	N/A	-$377.94M	-$3.45	N/A

Agios Pharmaceuticals has a beta of 0.6, indicating that its share price is 40% less volatile than the broader market. Comparatively, Scholar Rock has a beta of 0.67, indicating that its share price is 33% less volatile than the broader market.

Agios Pharmaceuticals presently has a consensus target price of $41.25, indicating a potential upside of 24.51%. Scholar Rock has a consensus target price of $58.77, indicating a potential upside of 5.06%. Given Agios Pharmaceuticals' higher possible upside, equities analysts clearly believe Agios Pharmaceuticals is more favorable than Scholar Rock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agios Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.55
Scholar Rock	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	4 Strong Buy rating(s)	3.13

Scholar Rock has a net margin of 0.00% compared to Agios Pharmaceuticals' net margin of -418.24%. Agios Pharmaceuticals' return on equity of -35.67% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Agios Pharmaceuticals	-418.24%	-35.67%	-33.06%
Scholar Rock	N/A	-160.19%	-87.18%

In the previous week, Agios Pharmaceuticals had 1 more articles in the media than Scholar Rock. MarketBeat recorded 8 mentions for Agios Pharmaceuticals and 7 mentions for Scholar Rock. Scholar Rock's average media sentiment score of 1.43 beat Agios Pharmaceuticals' score of 1.43 indicating that Scholar Rock is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Agios Pharmaceuticals	7 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Scholar Rock	6 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

91.1% of Scholar Rock shares are held by institutional investors. 5.4% of Agios Pharmaceuticals shares are held by insiders. Comparatively, 10.3% of Scholar Rock shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Scholar Rock beats Agios Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does Agios Pharmaceuticals compare to Cogent Biosciences?

Agios Pharmaceuticals (NASDAQ:AGIO) and Cogent Biosciences (NASDAQ:COGT) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, institutional ownership, media sentiment, earnings, profitability and dividends.

Cogent Biosciences has lower revenue, but higher earnings than Agios Pharmaceuticals. Cogent Biosciences is trading at a lower price-to-earnings ratio than Agios Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agios Pharmaceuticals	$98.34M	20.11	-$412.78M	-$7.01	N/A
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.16	N/A

Agios Pharmaceuticals currently has a consensus price target of $41.25, suggesting a potential upside of 24.51%. Cogent Biosciences has a consensus price target of $51.56, suggesting a potential upside of 47.51%. Given Cogent Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Cogent Biosciences is more favorable than Agios Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agios Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.55
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75

In the previous week, Agios Pharmaceuticals had 3 more articles in the media than Cogent Biosciences. MarketBeat recorded 8 mentions for Agios Pharmaceuticals and 5 mentions for Cogent Biosciences. Cogent Biosciences' average media sentiment score of 1.57 beat Agios Pharmaceuticals' score of 1.43 indicating that Cogent Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Agios Pharmaceuticals	7 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cogent Biosciences	4 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Agios Pharmaceuticals has a beta of 0.6, suggesting that its stock price is 40% less volatile than the broader market. Comparatively, Cogent Biosciences has a beta of 0.31, suggesting that its stock price is 69% less volatile than the broader market.

Cogent Biosciences has a net margin of 0.00% compared to Agios Pharmaceuticals' net margin of -418.24%. Agios Pharmaceuticals' return on equity of -35.67% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Agios Pharmaceuticals	-418.24%	-35.67%	-33.06%
Cogent Biosciences	N/A	-84.47%	-47.72%

Summary

Cogent Biosciences beats Agios Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

Get Agios Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AGIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AGIO vs. The Competition

Export

Metric	Agios Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.98B	$4.02B	$7.25B	$12.89B
Dividend Yield	N/A	3.61%	2.53%	8.57%
P/E Ratio	-4.73	12.72	273.59	25.45
Price / Sales	20.11	1,361.39	675.80	123.67
Price / Cash	N/A	105.29	76.98	52.10
Price / Book	1.93	16.29	12.89	6.14
Net Income	-$412.78M	-$22.72M	$3.47B	$349.01M
7 Day Performance	-3.35%	-1.38%	-0.33%	-1.47%
1 Month Performance	8.48%	11.06%	6.51%	2.47%
1 Year Performance	-18.42%	53.71%	25.19%	15.84%

Agios Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AGIO Agios Pharmaceuticals	2.6572 of 5 stars	$33.13 -2.9%	$41.25 +24.5%	-13.0%	$1.98B	$98.34M	N/A	390	Positive News
RYTM Rhythm Pharmaceuticals	2.8877 of 5 stars	$111.44 +1.3%	$142.44 +27.8%	+1.2%	$7.54B	$189.76M	N/A	140	Positive News Insider Trade
ORKA Oruka Therapeutics	2.8915 of 5 stars	$102.42 -5.1%	$134.30 +31.1%	+488.9%	$7.15B	N/A	N/A	N/A	Positive News Analyst Forecast Insider Trade
CGON CG Oncology	3.1016 of 5 stars	$78.23 -2.0%	$83.18 +6.3%	+171.6%	$7.07B	$4.04M	N/A	61	Positive News
SRRK Scholar Rock	1.9918 of 5 stars	$58.20 +3.0%	$58.77 +1.0%	+69.4%	$6.88B	N/A	N/A	140	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AGIO) was last updated on 9/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Agios Pharmaceuticals (AGIO) Competitors

AGIO vs. RYTM, ORKA, CGON, SRRK, and COGT

How does Agios Pharmaceuticals compare to Rhythm Pharmaceuticals?

Summary

How does Agios Pharmaceuticals compare to Oruka Therapeutics?

Summary

How does Agios Pharmaceuticals compare to CG Oncology?

Summary

How does Agios Pharmaceuticals compare to Scholar Rock?

Summary

How does Agios Pharmaceuticals compare to Cogent Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AGIO vs. The Competition

Agios Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Agios Pharmaceuticals (AGIO) Competitors

AGIO vs. RYTM, ORKA, CGON, SRRK, and COGT

How does Agios Pharmaceuticals compare to Rhythm Pharmaceuticals?

Which has better earnings & valuation, AGIO or RYTM?

Does the media favor AGIO or RYTM?

Which has more volatility & risk, AGIO or RYTM?

Is AGIO or RYTM more profitable?

Do analysts rate AGIO or RYTM?

Summary

How does Agios Pharmaceuticals compare to Oruka Therapeutics?

Does the media refer more to ORKA or AGIO?

Do analysts recommend ORKA or AGIO?

Do insiders and institutionals hold more shares of ORKA or AGIO?

Which has preferable earnings and valuation, ORKA or AGIO?

Which has more volatility & risk, ORKA or AGIO?

Is ORKA or AGIO more profitable?

Summary

How does Agios Pharmaceuticals compare to CG Oncology?

Do institutionals and insiders have more ownership in AGIO or CGON?

Do analysts rate AGIO or CGON?

Which has higher earnings & valuation, AGIO or CGON?

Is AGIO or CGON more profitable?

Does the media prefer AGIO or CGON?

Which has more volatility & risk, AGIO or CGON?

Summary

How does Agios Pharmaceuticals compare to Scholar Rock?

Which has higher valuation and earnings, AGIO or SRRK?

Which has more risk and volatility, AGIO or SRRK?

Do analysts prefer AGIO or SRRK?

Is AGIO or SRRK more profitable?

Does the media favor AGIO or SRRK?

Do institutionals and insiders believe in AGIO or SRRK?

Summary

How does Agios Pharmaceuticals compare to Cogent Biosciences?

Which has preferable valuation and earnings, AGIO or COGT?

Do analysts recommend AGIO or COGT?

Does the media refer more to AGIO or COGT?

Which has more risk and volatility, AGIO or COGT?

Is AGIO or COGT more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AGIO vs. The Competition

Agios Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools